Wellington Management Group LLP Invests $1.18 Million in Evolus, Inc. $EOLS

Posted by on Sep 12th, 2026

Wellington Management Group LLP purchased a new stake in Evolus, Inc. (NASDAQ:EOLS – Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 169,934 shares of the company’s stock, valued at approximately $1,179,000.

A number of other institutional investors have also modified their holdings of the business. Nantahala Capital Management LLC acquired a new stake in Evolus during the second quarter worth about $38,878,026. AWH Capital L.P. bought a new position in Evolus in the second quarter worth about $4,337,500. Seven Fleet Capital Management LP acquired a new position in Evolus in the second quarter valued at approximately $541,716. Pure Financial Advisors LLC acquired a new position in Evolus in the second quarter valued at approximately $124,000. Finally, Corient Private Wealth LP bought a new position in shares of Evolus during the second quarter valued at approximately $437,000. Institutional investors own 90.69% of the company’s stock.

Evolus Trading Down 0.9%

NASDAQ EOLS opened at $7.84 on Friday. The company has a 50-day moving average price of $7.42 and a two-hundred day moving average price of $6.23. Evolus, Inc. has a 52 week low of $3.86 and a 52 week high of $9.31. The stock has a market cap of $517.83 million, a price-to-earnings ratio of -15.08 and a beta of 1.42.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on EOLS. Wall Street Zen upgraded Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Evolus in a research note on Tuesday, August 25th. Finally, BTIG Research reiterated a “buy” rating and issued a $13.00 target price on shares of Evolus in a research note on Wednesday, June 17th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

Get Our Latest Report on Evolus

Insider Transactions at Evolus

In other news, insider David Moatazedi sold 105,108 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total value of $950,176.32. Following the completion of the transaction, the insider owned 499,592 shares of the company’s stock, valued at approximately $4,516,311.68. This represents a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 5.00% of the company’s stock.

About Evolus

(Free Report)

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.

Featured Articles

Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc. (NASDAQ:EOLS – Free Report).

Institutional Ownership by Quarter for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.